SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca(2+) flux to mitochondria

Inactivating mutations in SMARCA4 and concurrent epigenetic silencing of SMARCA2 characterize subsets of ovarian and lung cancers. Concomitant loss of these key subunits of SWI/SNF chromatin remodeling complexes in both cancers is associated with chemotherapy resistance and poor prognosis. Here, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Xue, Yibo, Morris, Jordan L., Yang, Kangning, Fu, Zheng, Zhu, Xianbing, Johnson, Fraser, Meehan, Brian, Witkowski, Leora, Yasmeen, Amber, Golenar, Tunde, Coatham, Mackenzie, Morin, Geneviève, Monast, Anie, Pilon, Virginie, Fiset, Pierre Olivier, Jung, Sungmi, Gonzalez, Anne V., Camilleri-Broet, Sophie, Fu, Lili, Postovit, Lynne-Marie, Spicer, Jonathan, Gotlieb, Walter H., Guiot, Marie-Christine, Rak, Janusz, Park, Morag, Lockwood, William, Foulkes, William D., Prudent, Julien, Huang, Sidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438089/
https://www.ncbi.nlm.nih.gov/pubmed/34518526
http://dx.doi.org/10.1038/s41467-021-25260-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438089/
https://www.ncbi.nlm.nih.gov/pubmed/34518526
http://dx.doi.org/10.1038/s41467-021-25260-9

Ejemplares similares